Lipoprotein (a), Lp(a), is an important independent risk factor for premature atherosclerotic cardiovascular disease (ASCVD), including heart attacks, stroke and calcific aortic valve stenosis. Guidelines on whom to screen for Lp(a) are evolving and new therapies are emerging. In the 4th session of the FH Global Summit, Dr. Sotiorios (Sam) Tsimikas will highlight “Emerging treatments to reduce Lp(a)-mediated CVD risk” and cover:
- The wide heterogeneity of current lipid-lowering drugs on Lp(a) and their clinical significance
- The debate: What is the required degree of Lp(a) lowering to meaningfully reduce CHD outcomes?
Dr. Tsimikas will be joined by an individual with high Lp(a), Cyd Isleib, as well as Dr. Mary McGowan, the FH Foundation’s Chief Medical Officer, for a roundtable discussion on the real world implications of diagnosis and care of Lp(a).